Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.65 |
| ▸ | STK17B | O94768 | 1/20 | 0.65 |
| ▸ | STK10 | O94804 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186516 | 1.00 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL29623456 | 1.00 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL29623540 | 1.00 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL6990366 | 1.00 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL1383708 | 1.00 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL6987775 | 0.96 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL7219510 | 0.96 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL6987341 | 0.96 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL6994030 | 0.96 | EGFR (0.73) | EGFRCITGAKEPHB6ABCC4 | |
| SCHEMBL6990969 | 0.96 | EGFR (0.70) | EGFRCITGAKEPHB6ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025641-A1 | COMBINATIONS OF AN ERK INHIBITOR AND AN EGFR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | US | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | claimed |
| EP-1478398-B1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-05-06 | — | — | EP | claimed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | claimed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | ERBB2, EGFR, ERBB4 | EGFR 2/4885CIT 1013/4885GAK 699/4885 |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, CHRM2 | EGFR 2/4885CIT 145/4885GAK 123/4885 |
| US-20100099651-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, GRK5, PRKCH | EGFR 63/4885CIT 503/4885GAK 696/4885 |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | EGFR 52/4885CIT 349/4885GAK 299/4885 |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | ERBB2, EGFR, ERBB3 | EGFR 2/4885CIT 653/4885GAK 586/4885 |
| US-20110281860-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | EGFR, ERBB4, GRK5 | EGFR 1/4885CIT 205/4885GAK 680/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | EGFR 53/4885CIT 628/4885GAK 749/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | EGFR 43/4885CIT 428/4885GAK 436/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885CIT 1946/4885GAK 1286/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | EGFR 3691/4885CIT 4295/4885GAK 4053/4885 |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | EGFR 137/4885CIT 432/4885GAK 205/4885 |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, ERBB2 | EGFR 2/4885CIT 221/4885GAK 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.